Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 07, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the filing of its 2025 Universal Registration Document with the Autorité des marches financiers (AMF; filing n° D.26-0221).
GENFIT Announces Publication of the 2025 Universal Registration Document
